cancers-logo

Journal Browser

Journal Browser

Clinical Research of Brachytherapy in Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 30 October 2026 | Viewed by 962

Special Issue Editors


E-Mail Website
Guest Editor
Department of Radiotherapy, Medical University of Lublin, 20-081 Lublin, Poland
Interests: personalized treatment of neoplasm-combined treatment of neoplasm

E-Mail Website
Co-Guest Editor
Department of Radiotherapy, Medical University of Lublin, 20-081 Lublin, Poland
Interests: brachytherapy; interventional radiotherapy; combined treatment

E-Mail
Guest Editor Assistant
Department of Radiotherapy, Medical University of Lublin, 20-081 Lublin, Poland
Interests: brachytherapy; interventional radiotherapy; combined treatment

Special Issue Information

Dear Colleagues,

Despite technological advances in external beam radiotherapy, which involve new imaging, immobilization, and dose delivery techniques, brachytherapy remains a significant method of radiotherapy due to its high conformality. Thanks to improvements in imaging techniques, applicator miniaturization, and the increasing use of new ultra-low dose rate radioactive sources, the capabilities of brachytherapy have expanded in recent years to include new indications and locations. Local treatment, including brachytherapy, is also becoming more important in the treatment of metastatic disease, where advances in systemic treatment have significantly increased survival rates. In this context, brachytherapy, also known as interventional radiotherapy, plays a particularly important role in local disease control. Combined with stereotactic radiotherapy, chemotherapy, targeted therapy, and immunotherapy, this enables metastatic disease to become a chronic condition with long-term survival and a good quality of life. Therefore, I encourage you to publish research that expands the role of brachytherapy in both existing and new indications.

We are pleased to invite you to publish articles on the different clinical indications of brachytherapy.

This Special Issue aims to present the current place of brachytherapy in various cancers, with a particular focus on combination therapy (combined with radiotherapy and/or systemic treatment) for new indications, as well as expanding and enhancing its use for existing ones. Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Interventional radiotherapy—Brachytherapy—LDR, HDR.
  • Oligometastatic disease and concomitant treatment.
  • Immunotherapy and brachytherapy.
  • Personalized treatment and brachytherapy in neoplasm.

We look forward to receiving your contributions.

Dr. Ludmiła Grzybowska-Szatkowska
Guest Editor

Dr. Paweł Cisek
Co-Guest Editor

Dr. Aleksandra Kozłowska
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • brachytherapy
  • LDR
  • HDR
  • genitourinary cancers
  • breast cancer
  • skin cancer
  • gastrointestinal cancers
  • oligometastatic disease
  • personalized treatment and neoplasm

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 5785 KB  
Article
The Role of High-Dose-Rate Brachytherapy (Interventional Radiotherapy) in the Reirradiation of Liver Metastases
by Paweł Cisek, Izabela Kordzińska-Cisek, Aleksandra Kozłowska and Ludmiła Grzybowska-Szatkowska
Cancers 2025, 17(24), 4013; https://doi.org/10.3390/cancers17244013 - 16 Dec 2025
Viewed by 716
Abstract
Background: This study aimed to analyse treatment outcomes, determine prognostic factors and assess the toxicity of reirradiation using high-dose-rate (HDR) brachytherapy for liver metastases in the oligometastatic stage of disease. Materials and Methods: The study included 59 patients who had previously [...] Read more.
Background: This study aimed to analyse treatment outcomes, determine prognostic factors and assess the toxicity of reirradiation using high-dose-rate (HDR) brachytherapy for liver metastases in the oligometastatic stage of disease. Materials and Methods: The study included 59 patients who had previously undergone SBRT (stereotactic body radiation therapy) or HDR brachytherapy and experienced progression within (type 1) or outside (type 2) the irradiated area, but in a different location within the liver. Patients were divided according to the type of reirradiation and the reason for treatment. Local control (LC), progression-free survival (PFS) and overall survival (OS) were analysed in relation to the following factors: age; gender; performance status; tumour type; line of systemic treatment; location of extrahepatic metastases; type of reirradiation; time since previous irradiation; indication for treatment; size and number of metastases; dose; and degree of response to treatment. Treatment toxicity and the influence of dose, irradiation volume, number of metastases, time since previous radiotherapy and dose to the non-irradiated part of the liver on hepatic toxicity were also assessed. Results: With a median follow-up period of 13 months, the median LC, PFS and OS were 9, 8 and 13 months, respectively. The respective rates of partial regression (PR), stable disease (SD) and progressive disease (PD) were 32%, 44% and 12%. The most significant factors influencing LC were the degree of tumour shrinkage, with PFS influenced by the degree of tumour shrinkage and a low number of metastases, and OS influenced by the degree of tumour shrinkage, a low number of metastases and one to two lines of systemic therapy. Treatment toxicity was low, and there was no strong correlation between the dosimetric parameters of the treatment plan and the biochemical parameters of liver function. Conclusions: Brachytherapy is a safe and effective method of re-irradiating liver metastases. However, due to the limitations of the study, further investigation is required. Full article
(This article belongs to the Special Issue Clinical Research of Brachytherapy in Cancer)
Show Figures

Graphical abstract

Back to TopTop